GlassScriptPhysician profile
Narciso Gonzalez
NPI 1316128549
$5,855.46
in general payments reported to CMS, 2019-2025
35 companies · $561 in 2025
The $561 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,841 · 2020: $637 · 2021: $719 · 2022: $1,010 · 2023: $763 · 2024: $324 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,492.00 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Abbott Laboratories | $1,227.84 | 2019-2025 | Proclaim, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $623.84 | 2019-2024 | Relistor |
| Medtronic Vascular, INC. | $312.20 | 2019 | |
| Si-Bone, INC. | $301.49 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $250.37 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $192.99 | 2019-2024 | Xtampza, Belbuca |
| Assertio Therapeutics, INC. | $166.98 | 2019 | |
| Pfizer INC. | $137.71 | 2019-2021 | |
| Glaxosmithkline, LLC. | $119.08 | 2022 | |
| Nalu Medical, INC. | $80.30 | 2022-2024 | Nalu Neurostimulation System |
| Spinal Simplicity, LLC | $79.58 | 2025 | Ha Minuteman G3-R |
| Horizon Therapeutics Plc | $77.80 | 2019-2021 | |
| Fidia Pharma USA INC. | $70.07 | 2020-2025 | Hymovis, Triluron |
| Biodelivery Sciences International, INC. | $63.71 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $59.98 | 2023-2025 | Qutenza |
| Almatica Pharma LLC | $59.41 | 2021 | |
| Hikma Pharmaceuticals USA | $55.81 | 2022 | |
| Bioventus LLC | $55.18 | 2023-2024 | Supartz Fx Sodium Hyaluronate, Supartz Fx Sodium Hyaluronate |
| Medtronic, INC. | $52.62 | 2021-2022 | |
| Globus Medical, INC. | $43.42 | 2025 | Senza |
| Pacira Therapeutics, INC. | $39.49 | 2019-2020 | |
| Stryker Corporation | $34.78 | 2021-2025 | Mild Device Kit |
| Azurity Pharmaceuticals, INC. | $32.84 | 2023 | Horizant |
| Mdd US Operations, LLC | $31.70 | 2019-2020 | |
| Grt US Holding, INC. | $30.47 | 2020-2022 | |
| Mml US, INC. | $29.00 | 2025 | Reactiv8 |
| Saluda Medical Americas, INC. | $27.58 | 2024 | Evoke |
| Astrazeneca Pharmaceuticals LP | $23.36 | 2019-2020 | |
| Medtronic USA, INC. | $17.15 | 2020 | |
| Spr Therapeutics, INC | $15.73 | 2025 | Sprint Pns System |
| Biocompatibles, INC. | $13.62 | 2019 | |
| Shionogi INC | $13.52 | 2019 | |
| Redhill Biopharma INC. | $12.42 | 2021 | |
| Zyla Life Sciences, INC. | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narciso Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.